Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Identifieur interne : 000275 ( France/Analysis ); précédent : 000274; suivant : 000276Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Auteurs : Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 2003-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cartographie, Homme.
English descriptors
- KwdEn :
Abstract
Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18F‐dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18F‐dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen 18F‐dopa uptake (Ki) between baseline and 2‐year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region‐of‐interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (−13.4%; n = 68) compared with levodopa (−20.3%; n = 59; 95% confidence interval [CI], 0.65–13.06). Statistical parametric mapping localized lesser reductions in 18F‐dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, −14.1%; levodopa, −22.9%; 95% CI, 4.24–13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F‐dopa PET. Ann Neurol 2003
Url:
DOI: 10.1002/ana.10609
Affiliations:
- Allemagne, Autriche, Canada, France, Royaume-Uni, États-Unis
- Angleterre, Bade-Wurtemberg, District de Tübingen, Floride, Grand Londres, Géorgie (États-Unis), Midi-Pyrénées, Occitanie (région administrative), Ontario, Tyrol (Land)
- Innsbruck, Londres, Orsay, Toronto, Toulouse, Ulm
- Université d'Ulm, Université de Toronto, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001225
- to stream Istex, to step Curation: 001225
- to stream Istex, to step Checkpoint: 000E30
- to stream Main, to step Merge: 003225
- to stream PascalFrancis, to step Corpus: 000A43
- to stream PascalFrancis, to step Curation: 000280
- to stream PascalFrancis, to step Checkpoint: 000917
- to stream Main, to step Merge: 003303
- to stream Main, to step Curation: 002E27
- to stream Main, to step Exploration: 002E27
- to stream France, to step Extraction: 000275
Links to Exploration step
ISTEX:0787EB91885A5AF7606EBCBF69CF2E45C0539042Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study</title><author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name></author><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></author><author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name></author><author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name></author><author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name></author><author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0787EB91885A5AF7606EBCBF69CF2E45C0539042</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10609</idno><idno type="url">https://api-v5.istex.fr/document/0787EB91885A5AF7606EBCBF69CF2E45C0539042/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001225</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001225</idno><idno type="wicri:Area/Istex/Curation">001225</idno><idno type="wicri:Area/Istex/Checkpoint">000E30</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E30</idno><idno type="wicri:doubleKey">0364-5134:2003:Whone A:slower:progression:of</idno><idno type="wicri:Area/Main/Merge">003225</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0498653</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A43</idno><idno type="wicri:Area/PascalFrancis/Curation">000280</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000917</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000917</idno><idno type="wicri:doubleKey">0364-5134:2003:Whone A:slower:progression:of</idno><idno type="wicri:Area/Main/Merge">003303</idno><idno type="wicri:Area/Main/Curation">002E27</idno><idno type="wicri:Area/Main/Exploration">002E27</idno><idno type="wicri:Area/France/Extraction">000275</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study</title><author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Neurology, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Neurology, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name><affiliation wicri:level="4"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universität Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name><affiliation><wicri:noCountry code="subField">Hamilton</wicri:noCountry></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region></placeName><wicri:orgArea>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>CEA‐CNRS URA 2210, Service Hospitalier F. Joliot, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>CEA‐CNRS URA 2210, Service Hospitalier F. Joliot, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Clinical Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>University of South Florida and Tampa General Healthcare, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-07">2003-07</date><biblScope unit="volume">54</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="93">93</biblScope><biblScope unit="page" to="101">101</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">0787EB91885A5AF7606EBCBF69CF2E45C0539042</idno><idno type="DOI">10.1002/ana.10609</idno><idno type="ArticleID">ANA10609</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Aminoacid</term><term>Cartography</term><term>Catecholamine</term><term>Comparative study</term><term>D2 Dopamine receptor</term><term>Dopa</term><term>Dopamine</term><term>Dopamine agonist</term><term>Double blind study</term><term>Emission tomography</term><term>Human</term><term>Levodopa</term><term>Parkinson disease</term><term>Positron</term><term>Prognosis</term><term>Putamen</term><term>Ropinirole</term><term>Uptake</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Aminoacide</term><term>Captation</term><term>Cartographie</term><term>Catécholamine</term><term>Dopa</term><term>Dopamine</term><term>Etude comparative</term><term>Etude double insu</term><term>Homme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Positon</term><term>Pronostic</term><term>Putamen</term><term>Ropinirole</term><term>Récepteur dopaminergique D2</term><term>Stimulant dopaminergique</term><term>Tomoscintigraphie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cartographie</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18F‐dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18F‐dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen 18F‐dopa uptake (Ki) between baseline and 2‐year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region‐of‐interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (−13.4%; n = 68) compared with levodopa (−20.3%; n = 59; 95% confidence interval [CI], 0.65–13.06). Statistical parametric mapping localized lesser reductions in 18F‐dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, −14.1%; levodopa, −22.9%; 95% CI, 4.24–13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F‐dopa PET. Ann Neurol 2003</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Canada</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>District de Tübingen</li><li>Floride</li><li>Grand Londres</li><li>Géorgie (États-Unis)</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Ontario</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Londres</li><li>Orsay</li><li>Toronto</li><li>Toulouse</li><li>Ulm</li></settlement><orgName><li>Université d'Ulm</li><li>Université de Toronto</li><li>Université de médecine d'Innsbruck</li></orgName></list><tree><noCountry><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name></region><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></country><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name></region><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></country><country name="Canada"><noRegion><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name></region></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:0787EB91885A5AF7606EBCBF69CF2E45C0539042
|texte= Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
}}
| This area was generated with Dilib version V0.6.29. |  |